amlexanox has been researched along with Liver Cirrhosis in 1 studies
amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, Z | 1 |
| Qi, J | 1 |
| Zhao, J | 1 |
| Lim, CW | 1 |
| Kim, JW | 1 |
| Kim, B | 1 |
1 other study available for amlexanox and Liver Cirrhosis
| Article | Year |
|---|---|
Dual TBK1/IKKÉ› inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice.
Topics: Aminopyridines; Animals; Bile Ducts; Carbon Tetrachloride; Hepatic Stellate Cells; I-kappa B Kinase; | 2020 |